✦ LIBER ✦

Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells

✍ Scribed by Vilma Maldonado; Jorge Meléndez-Zajgla; Arturo Ortega

Book ID: 114071350
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 320 KB
Volume: 381
Category: Article
ISSN: 0027-5107
DOI: 10.1016/s0027-5107(97)00150-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aspirin Prevents Apoptosis and NF-κB Act

Aspirin Prevents Apoptosis and NF-κB Activation Induced by H2O2 in HeLa Cells

✍ Kutuk, Ozgur; Basaga, Huveyda 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 330 KB

Contribution of NF-κB and p53 in the glu

Contribution of NF-κB and p53 in the glutamate-induced apoptosis

✍ Daniela Uberti; Mariagrazia Grilli; Maurizio Memo 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 403 KB

Role of p53 and NF-κB in epigallocatechi

Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells

✍ Hastak, Kedar; Gupta, Sanjay; Ahmad, Nihal; Agarwal, Mukesh K; Agarwal, Munna L; 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 389 KB

Salinomycin inhibits Akt/NF-κB and induc

Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells

✍ Parajuli, Bidur; Lee, Hyun-Gyo; Kwon, Sang-Hoon; Cha, Soon-Do; Shin, So-Jin; Lee 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 684 KB

Ursolic acid induces apoptosis by activa

Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expressions and suppressing NF-κB mediated activation of bcl-2 in B16F-10 melanoma cells

✍ K.A. Manu; Girija Kuttan 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 628 KB

Plumbagin-induced apoptosis of human bre

Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-κB and Bcl-2

✍ Aamir Ahmad; Sanjeev Banerjee; Zhiwei Wang; Dejuan Kong; Fazlul H. Sarkar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB

## Abstract Breast cancer remains the major cause of cancer‐related deaths in women world‐wide. The heterogeneity of breast cancer has further complicated the progress of target‐based therapies. Triple negative breast cancers, lacking estrogen receptor, progesterone receptor and the Her‐2/neu (ErbB